Literature DB >> 33553240

Living Donor Liver Transplantation for Hepatocellular Carcinoma: Appraisal of the United Network for Organ Sharing Modified TNM Staging.

Abu Bakar Hafeez Bhatti1, Anum Waheed1, Nasir Ayub Khan2.   

Abstract

Background: In deceased donor liver transplantation (DDLT), transplant eligibility for T3-T4 HCC requires successful downstaging (DS). Living donor liver transplantation (LDLT) can be considered selectively in these patients without DS, but its role is not defined. The objective of the current study was to assess outcomes of LDLT for HCC based on UNOS staging with no prior DS. Materials and
Methods: Patients who underwent LDLT for HCC (n = 262) were staged based on modified UNOS TNM staging. High-risk factors were identified and 5-year recurrence free survival was compared in patients with T2-T4 HCC.
Results: Median follow-up was 30.2 (16.4-46.3) months. Recurrence rate in T1, T2, T3, T4a, and T4b HCC was 0, 10.1, 16.1, 5.9, and 37.5% (P = 0.02), respectively. On multivariate analysis, AFP > 600 ng/mL [HR:11.7, P < 0.001] and T4b HCC (macrovascular invasion) [HR = 5.6, P = 0.03] were predictors of recurrence. After exclusion of AFP > 600 ng/mL, 5-year RFS for T2, T3, and T4a HCC was 94, 86, and 92% (P = 0.3). Rate of microvascular invasion between T2 and T3 HCC was 24.3 vs. 53.6% (P = 0.005), and between T2 and T4a HCC was 24.3 vs. 36.7% (P = 0.2). Overall, 26 (19.4%) patients were overstaged and 23 (17.1%) were understaged on preoperative imaging. The 5-year RFS in patients with identical preoperative and histopathological staging was 94, 87, and 94% (P = 0.6).
Conclusion: LDLT without prior DS leads to comparable survival for UNOS T2, T3, and T4a HCC as long as AFP is < 600 ng/mL.
Copyright © 2021 Bhatti, Waheed and Khan.

Entities:  

Keywords:  down staging; hepatocellula carcinoma; liver tranpslant; recurrence free survival; united network for organ sharing

Year:  2021        PMID: 33553240      PMCID: PMC7859519          DOI: 10.3389/fsurg.2020.622170

Source DB:  PubMed          Journal:  Front Surg        ISSN: 2296-875X


  24 in total

Review 1.  What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma?

Authors:  Neil Mehta; Francis Y Yao
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-02-21

2.  AASLD guidelines for the treatment of hepatocellular carcinoma.

Authors:  Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

3.  Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.

Authors:  Francis Y Yao; Neil Mehta; Jennifer Flemming; Jennifer Dodge; Bilal Hameed; Oren Fix; Ryutaro Hirose; Nicholas Fidelman; Robert K Kerlan; John P Roberts
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

4.  The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study.

Authors:  Gonzalo Sapisochin; Nicolas Goldaracena; Jerome M Laurence; Martin Dib; Andrew Barbas; Anand Ghanekar; Sean P Cleary; Les Lilly; Mark S Cattral; Max Marquez; Markus Selzner; Eberhard Renner; Nazia Selzner; Ian D McGilvray; Paul D Greig; David R Grant
Journal:  Hepatology       Date:  2016-06-30       Impact factor: 17.425

5.  Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.

Authors:  Tadaaki Arizumi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
Journal:  Dig Dis       Date:  2017-10-17       Impact factor: 2.404

Review 6.  Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis.

Authors:  Jack P Silva; Nicholas G Berger; Susan Tsai; Kathleen K Christians; Callisia N Clarke; Harveshp Mogal; Sarah White; William Rilling; T Clark Gamblin
Journal:  HPB (Oxford)       Date:  2017-05-25       Impact factor: 3.647

7.  Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion.

Authors:  Derek DuBay; Charbel Sandroussi; Lakhbir Sandhu; Sean Cleary; Markus Guba; Mark S Cattral; Ian McGilvray; Anand Ghanekar; Markus Selzner; Paul D Greig; David R Grant
Journal:  Ann Surg       Date:  2011-01       Impact factor: 12.969

8.  Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.

Authors:  Neil Mehta; Jennifer L Dodge; John P Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Hepatology       Date:  2019-02-10       Impact factor: 17.425

9.  Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.

Authors:  Kenichi Takayasu; Shigeki Arii; Masatoshi Kudo; Takafumi Ichida; Osamu Matsui; Namiki Izumi; Yutaka Matsuyama; Michiie Sakamoto; Osamu Nakashima; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

10.  Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study.

Authors:  Rebecca A Miksad; Sadahisa Ogasawara; Fang Xia; Marc Fellous; Fabio Piscaglia
Journal:  BMC Cancer       Date:  2019-08-13       Impact factor: 4.430

View more
  1 in total

1.  Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion.

Authors:  Abu Bakar Hafeez Bhatti; Wajih Naqvi; Nusrat Yar Khan; Haseeb Haider Zia; Faisal Saud Dar; Zahid Amin Khan; Atif Rana
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-12       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.